Quantification of EBV DNA in EBV-positive lymphomas, EBV-negative lymphomas, and nonlymphomatous conditions
. | . | Median level of plasma EBV DNA/mL (range) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnoses . | N . | Pretreatment . | Peak* . | Trough† . | CR latest level . | NR/death latest level/death . | ||||
| EBV-positive lymphomas | ||||||||||
| NK cell lymphoma | 23 | 6.1 × 107 (2.7 × 105 - 7.2 × 1010) | 3.9 × 108 (2.8 × 106 - 2.4 × 1011) | 0 (0-2.1 × 108) | 0 | 2.8 × 108 (6.7 × 107 - 2.4 × 1011) | ||||
| Angioimmunoblastic TCL | 6 | 2.7 × 109 (6.7 × 107 - 4.7 × 1010) | 5.3 × 109 (6.7 × 107 - 6.5 × 1010) | 0 (0-1.5 × 108) | 0 | 3.7 × 109 (2.3 × 106 - 1.5 × 1010) | ||||
| DLBCL | 4 | 2.2 × 106 (3.0 × 105 - 8.2 × 107) | 2.7 × 106 (3.0 × 105 - 4.6 × 1010) | 0 | 0 | NA | ||||
| HD | 4 | 2.3 × 107 (3.7 × 106 - 6.3 × 108) | 2.3 × 107 (3.7 × 106 - 6.7 × 108) | 0 | 0 | NA | ||||
| PTCL | 2 | 9.3 × 106, 3.3 × 108 | 1.3 × 108, 2.0 × 109 | 0, 1.6 × 108 | NA | 1.1 × 109 | ||||
| PTLD | 7 | 3.1 × 107 (0-8.3 × 1010) | 5.1 × 109 (3.1 × 107 - 1.4 × 1011) | 0 | 0 | 5.1 × 109 (9.1 × 108 - 1.4 × 1011) | ||||
| EBV-negative lymphomas | ||||||||||
| HD | 13 | 0 | 0 | 0 | 0 | 0 | ||||
| DLBCL | 14 | 0 | 0 | 0 | 0 | 0 | ||||
| PTCL | 7 | 0 | 0 | 0 | 0 | 0 | ||||
| Non-lymphomatous | ||||||||||
| HSCT | 16 | 0 | 5.8 × 106 (8.5 × 105 - 1.6 × 108) | 0 | 0 | 6.4 × 106 (0-1.2 × 109) | ||||
. | . | Median level of plasma EBV DNA/mL (range) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnoses . | N . | Pretreatment . | Peak* . | Trough† . | CR latest level . | NR/death latest level/death . | ||||
| EBV-positive lymphomas | ||||||||||
| NK cell lymphoma | 23 | 6.1 × 107 (2.7 × 105 - 7.2 × 1010) | 3.9 × 108 (2.8 × 106 - 2.4 × 1011) | 0 (0-2.1 × 108) | 0 | 2.8 × 108 (6.7 × 107 - 2.4 × 1011) | ||||
| Angioimmunoblastic TCL | 6 | 2.7 × 109 (6.7 × 107 - 4.7 × 1010) | 5.3 × 109 (6.7 × 107 - 6.5 × 1010) | 0 (0-1.5 × 108) | 0 | 3.7 × 109 (2.3 × 106 - 1.5 × 1010) | ||||
| DLBCL | 4 | 2.2 × 106 (3.0 × 105 - 8.2 × 107) | 2.7 × 106 (3.0 × 105 - 4.6 × 1010) | 0 | 0 | NA | ||||
| HD | 4 | 2.3 × 107 (3.7 × 106 - 6.3 × 108) | 2.3 × 107 (3.7 × 106 - 6.7 × 108) | 0 | 0 | NA | ||||
| PTCL | 2 | 9.3 × 106, 3.3 × 108 | 1.3 × 108, 2.0 × 109 | 0, 1.6 × 108 | NA | 1.1 × 109 | ||||
| PTLD | 7 | 3.1 × 107 (0-8.3 × 1010) | 5.1 × 109 (3.1 × 107 - 1.4 × 1011) | 0 | 0 | 5.1 × 109 (9.1 × 108 - 1.4 × 1011) | ||||
| EBV-negative lymphomas | ||||||||||
| HD | 13 | 0 | 0 | 0 | 0 | 0 | ||||
| DLBCL | 14 | 0 | 0 | 0 | 0 | 0 | ||||
| PTCL | 7 | 0 | 0 | 0 | 0 | 0 | ||||
| Non-lymphomatous | ||||||||||
| HSCT | 16 | 0 | 5.8 × 106 (8.5 × 105 - 1.6 × 108) | 0 | 0 | 6.4 × 106 (0-1.2 × 109) | ||||
N indicates number of cases; NK, natural killer cell; PTLD, posttransplantation lymphoproliferative disease; TCL, T-cell lymphoma; NA, not available; DLBCL, diffuse large B-cell lymphoma; HD, Hodgkin disease; PTCL, peripheral T-cell lymphoma.
Peak level was the highest level detectable, either at diagnosis or during treatment.
Trough level was the lowest level detected during the clinical course.